Advertisement
Canada markets closed

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7323
    -0.0000 (-0.01%)
     

  • CRUDE OIL

    83.84
    +0.27 (+0.32%)
     

  • Bitcoin CAD

    88,012.22
    +232.80 (+0.27%)
     

  • CMC Crypto 200

    1,390.20
    +7.63 (+0.55%)
     

  • GOLD FUTURES

    2,345.30
    +2.80 (+0.12%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,762.00
    +194.50 (+1.11%)
     

  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,780.35
    +151.87 (+0.40%)
     

  • CAD/EUR

    0.6825
    +0.0004 (+0.06%)
     

Today’s Research Reports on Stocks to Watch: Cronos and GW Pharmaceuticals

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / March 1, 2018 / It's been an exciting week for the marijuana sector in the market. Cronos shares skyrocket after the stock made its debut on the NASDAQ this week. GW Pharmaceuticals may not have seen big gains but the company had a huge announcement that the European Medicines Agency (EMA) has granted orphan drug designation for cannabidiol (CBD) for the treatment of tuberous sclerosis (TS). The company is currently recruiting a Phase 3 clinical trial of an adjunctive therapy called Epidiolex that is meant to treat seizures associated with TS.

RDI Initiates Coverage on:

Cronos Group
https://rdinvesting.com/report/?ticker=CRON

GW Pharmaceuticals Plc
https://rdinvesting.com/report/?ticker=GWPH

ADVERTISEMENT

Cronos made its big debut in the stock market on Tuesday, trading on the NASDAQ exchange. Shares surged 20.34% on Wednesday and saw additional gains in after-hours trading. The Canadian licensed marijuana producer made history for being the first marijuana company ever to list on a major U.S. stock exchange. The Securities and Exchange Commission granted the company approval to start trading on February 27th. According to the company's founder and chief executive, Mike Gorenstein, "It's very significant for the company and the whole industry. It's a huge moment — just shows the stigma is continuing to erode on cannabis." He also said to CNN, "We're the only pure play marijuana company to be traded on a U.S. exchange." Cronos Group has a market value of $1.2 billion and is involved with countries that do not have a federal ban on marijuana. This includes Israel, Australia, Germany and Canada. Beacon Securities analyst Vahan Ajamian wrote, "We imagine the SEC would have gone through a very thorough review/vetting process before allowing a cannabis company to list on a major U.S. exchange."

Access RDI's Cronos Group Research Report at:
https://rdinvesting.com/report/?ticker=CRON

GW Pharmaceuticals' shares closed down 1.58% on a little under 300,000 shares traded on Wednesday. It was on Tuesday that the company announced that the European Medicines Agency (EMA) has granted orphan drug designation for cannabidiol (CBD) for the treatment of tuberous sclerosis (TS). The company is now in the process of recruiting a Phase 3 clinical trial of an adjunctive therapy called Epidiolex for the treatment of seizures that are associated with tuberous sclerosis. Data from the trial is expected in the second half of the year and if the results are positive, the company plans to submit regulatory applications in 2019 for Epidiolex in TS in both the U.S. and Europe. CEO Justin Gover commented, "GW's decision to evaluate Epidiolex in patients with tuberous sclerosis is based on findings from the physician-led Epidiolex expanded access program where the results of this open-label use of Epidiolex in children with TS have been very encouraging. GW has successfully submitted regulatory applications for Epidiolex in both the US and Europe for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. TS represents a near term opportunity to expand the potential indications for Epidiolex and reflects GW's ongoing commitment to addressing the needs of patients with highly treatment-resistant seizures."

Access RDI's GW Pharmaceuticals Plc Research Report at:
https://rdinvesting.com/report/?ticker=GWPH

Our Actionable Research on Cronos Group (NASDAQ: CRON) and GW Pharmaceuticals Plc (NASDAQ: GWPH) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com